Funahashi Kimihiko, Nemoto Tetsuo, Koike Junichi, Kurihara Akiharu, Shiokawa Hiroyuki, Ushigome Mistunori, Kaneko Tomoaki, Arai Kenichiro, Nagashima Yasuo, Koda Takamaru, Suzuki Takayuki, Kagami Satoru, Suitsu Yu, Kaneko Hironori, Shibuya Toshikazu
Department of General and Gastroenterological Surgery, Toho University Medical Center, Omori Hospital, 6-11-1 Omorinishi, Otaku, Tokyo, 143-8541, Japan.
Department of Pathology, Toho University Medical Center, Omori Hospital, 6-11-1 Omorinishi, Otaku, Tokyo, 143-8541, Japan.
Surg Case Rep. 2015 Dec;1(1):14. doi: 10.1186/s40792-015-0025-5. Epub 2015 Feb 10.
Although successful treatment of squamous cell carcinoma (SCC) of the rectum using chemoradiation therapy (CRT) has been reported, a standard protocol has yet to be established. The aim is to ascertain the effectiveness of CRT with S-1 for three patients with SCC of the rectum.
We treated three female patients complaining of rectal bleeding. The patients were diagnosed as having primary SCC of the rectum by means of routine examinations; one of them was a very rare case because of the presence of two lesions in the lower rectum. We treated the patients using CRT with S1 at a radiation dose of 1.8 Gy/fraction given five times weekly (Monday to Friday) to a median dose of 59.4 (45 to 59.4) Gy; S-1 (80 mg/m(2)/day) was administered orally during radiation therapy. One of three patients had an adverse event involving massive hemorrhage from the tumor. All patients exhibited an excellent response to CRT with S-1; two patients had a complete response, and one patient had a partial response and underwent a posterior pelvic exenteration with advancement flap reconstruction as a salvage treatment. Pathological examination of the resected specimen and lymph nodes revealed no tumor cells indicating a pathological complete response. In this series, the response rate was 100%.
We suggest that CRT with S-1 be chosen as the first-line therapy for SCC of the rectum. However, a large study will be required to establish a safe and effective regimen.
尽管已有使用放化疗(CRT)成功治疗直肠鳞状细胞癌(SCC)的报道,但尚未确立标准方案。目的是确定CRT联合S-1治疗3例直肠SCC患者的有效性。
我们治疗了3例主诉直肠出血的女性患者。通过常规检查诊断这些患者为原发性直肠SCC;其中1例为非常罕见的病例,因为在直肠下段有两个病灶。我们对患者采用CRT联合S-1治疗,放疗剂量为1.8 Gy/次,每周5次(周一至周五),中位剂量为59.4(45至59.4)Gy;放疗期间口服S-1(80 mg/m²/天)。3例患者中有1例出现不良事件,即肿瘤大量出血。所有患者对CRT联合S-1均表现出良好反应;2例患者完全缓解,1例患者部分缓解,作为挽救治疗接受了后盆腔脏器清除术及推进皮瓣重建术。切除标本和淋巴结的病理检查未发现肿瘤细胞,提示病理完全缓解。在本系列中,缓解率为100%。
我们建议将CRT联合S-1作为直肠SCC的一线治疗方法。然而,需要进行大规模研究以确立安全有效的治疗方案。